Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of P53

Nature Communications

Volumn 6, Issue , 2015, Pages

  Fei, Qi ^a   Shang, Ke ^a   Zhang, Jianhua ^a   Chuai, Shannon ^a   Kong, Desheng ^a   Zhou, Tianlun ^a   Fu, Shijun ^a   Liang, Ying ^a   Li, Chong ^a   Chen, Zhi ^a   Zhao, Yuan ^a   Yu, Zhengtian ^a   Huang, Zheng ^a   Hu, Min ^a   Ying, Haiyan ^a   Chen, Zhui ^a   Zhang, Yun ^a   Xing, Feng ^a   Zhu, Jidong ^a   Xu, Haiyan ^a   Zhao, Kehao ^a   Lu, Chris ^a   Atadja, Peter ^a   Xiao, Zhi Xiong ^b   Li, En ^a   Shou, Jianyong ^a,c   more..

^a Novartis Institutes for Biomedical Research   (China)

^b SICHUAN UNIVERSITY   (China)

^c Zhang Jiang Hitech Park   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE METHYLTRANSFERASE; PROTEIN MDM2; PROTEIN P53; SETDB1 PROTEIN; UNCLASSIFIED DRUG; PROTEIN METHYLTRANSFERASE; SETDB1 PROTEIN, HUMAN;

CANCER; DEGRADATION; ENZYME ACTIVITY; GENE EXPRESSION; METHYLATION; MUTATION; PHYSIOLOGICAL RESPONSE; PROTEIN; TUMOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; GAIN OF FUNCTION MUTATION; GENE DOSAGE; GENE OVEREXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN STABILITY; TUMOR DIFFERENTIATION; ANIMAL; COPY NUMBER VARIATION; EXPERIMENTAL LIVER NEOPLASM; HCT116 CELL LINE; METABOLISM; NUDE MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DNA COPY NUMBER VARIATIONS; GENES, P53; HCT116 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE, NUDE; PROTEIN METHYLTRANSFERASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84973411774     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9651     Document Type: Article

References (42)

1. Brosh, R. & Rotter, V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9, 701-713 (2009).
2. Li, M. et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828-829 (2011).
3. Shen, H. M. & Ong, C. N. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res. 366, 23-44 (1996).
4. Bressac, B., Kew, M., Wands, J. & Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350, 429-431 (1991).
5. Hsu, I. C. et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427-428 (1991).
6. Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304-317 (2014).
7. Beckerman, R. & Prives, C. Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2, a000935 (2010).
8. Scoumanne, A. & Chen, X. Protein methylation: a new mechanism of p53 tumor suppressor regulation. Histol. Histopathol. 23, 1143-1149 (2008).
9. Taira, N. & Yoshida, K. Post-translational modifications of p53 tumor suppressor: determinants of its functional targets. Histol. Histopathol. 27, 437-443 (2012).
10. Chuikov, S. et al. Regulation of p53 activity through lysine methylation. Nature 432, 353-360 (2004).
11. Huang, J. et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 444, 629-632 (2006).
12. Huang, J. et al. p53 is regulated by the lysine demethylase LSD1. Nature 449, 105-108 (2007).
13. Huang, J. et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J. Biol. Chem. 285, 9636-9641 (2010).
14. Shi, X. et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 27, 636-646 (2007).
15. Kurash, J. K. et al. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol. Cell 29, 392-400 (2008).
16. Wang, H. et al. mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol. Cell 12, 475-487 (2003).
17. Sarraf, S. A. & Stancheva, I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol. Cell 15, 595-605 (2004).
18. Dodge, J. E., Kang, Y. K., Beppu, H., Lei, H. & Li, E. Histone H3-K9 methyltransferase ESET is essential for early development. Mol. Cell Biol. 24, 2478-2486 (2004).
19. Kim, H. A. et al. Notch1 counteracts WNT/beta-catenin signaling through chromatin modification in colorectal cancer. J. Clin. Invest. 122, 3248-3259 (2012).
20. Li, H. et al. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J. Biol. Chem. 281, 19489-19500 (2006).
21. Rodriguez-Paredes, M. et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene 33, 2807-2813 (2013).
22. Macgregor, S. et al. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat. Genet. 43, 1114-1118 (2011).
23. Ceol, C. J. et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471, 513-517 (2011).
24. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007-20012 (2007).
25. Gouas, D. A. et al. Effects of the TP53 p. R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis 31, 1475-1482 (2010).
26. Vaughan, C. A. et al. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem. Biophys. Res. Commun. 428, 6-10 (2012).
27. Vaughan, C. A. et al. p53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity. Arch. Biochem. Biophys. 518, 79-88 (2012).
28. Meek, D. W. Tumour suppression by p53: a role for the DNA damage response? Nat. Rev. Cancer 9, 714-723 (2009).
29. Yuan, P. et al. Eset partners with Oct4 to restrict extraembryonic trophoblast lineage potential in embryonic stem cells. Genes Dev. 23, 2507-2520 (2009).
30. Bilodeau, S., Kagey, M. H., Frampton, G. M., Rahl, P. B. & Young, R. A. SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state. Genes Dev. 23, 2484-2489 (2009).
31. Ivanov, G. S. et al. Methylation-acetylation interplay activates p53 in response to DNA damage. Mol. Cell Biol. 27, 6756-6769 (2007).
32. Wang, L. et al. Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation. J. Biol. Chem. 286, 38725-38737 (2011).
33. Rathert, P. et al. Protein lysine methyltransferase G9a acts on non-histone targets. Nat. Chem. Biol. 4, 344-346 (2008).
34. Matsui, T. et al. Proviral silencing in embryonic stem cells requires the histone methyltransferase ESET. Nature 464, 927-931 (2010).
35. Noh, H. J., Kim, K. A. & Kim, K. C. p53 Down-regulates SETDB1 gene expression during paclitaxel induced-cell death. Biochem. Biophys. Res. Commun. 446, 43-48 (2014).
36. Ames, B. N., Durston, W. E., Yamasaki, E. & Lee, F. D. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl Acad. Sci. USA 70, 2281-2285 (1973).
37. Montesano, R., Hainaut, P. & Wild, C. P. Hepatocellular carcinoma: from gene to public health. J. Natl Cancer Inst. 89, 1844-1851 (1997).
38. Kensler, T. W., Roebuck, B. D., Wogan, G. N. & Groopman, J. D. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol. Sci. 120, S28-S48.
39. Aguilar, F., Hussain, S. P. & Cerutti, P. Aflatoxin B1 induces the transversion of G->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl Acad. Sci. USA 90, 8586-8590 (1993).
40. Wiederschain, D. et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8, 498-504 (2009).
41. Klockenbusch, C. & Kast, J. Optimization of formaldehyde cross-linking for protein interaction analysis of non-tagged integrin beta1. J. Biomed. Biotechnol. 2010, 927585 (2010).
42. Fu, S. et al. Involvement of histone acetylation of Sox17 and Foxa2 promoters during mouse definitive endoderm differentiation revealed by MicroRNA profiling. PLoS ONE 6, e27965 (2011).